Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated strong financial performance, achieving a 21% increase in top-line revenue in Q3, bolstered by 13% growth in volume and a 5% rise in average selling prices. The company also reported its highest cash collections in history during October and delivered a positive GAAP net income, raising both its revenue and earnings guidance. Furthermore, the significant expansion of its sales force by approximately 50% is expected to drive future volume growth, reflecting the company's positive business fundamentals and optimistic outlook.

Bears say

CareDx Inc. reported Q3'25 testing volumes of 50,000, reflecting a modest year-over-year growth of 13% but falling short of expectations, which raises concerns about future growth potential. The company faces challenges with a significant reliance on its testing services and may struggle to commercialize new diagnostic solutions crucial for its expansion strategy, compounded by inconsistencies in management over the past three years. Additionally, with shares trading at 1.4 times the estimated 2026 revenue of $415 million, well below historical averages and relative to peers in the diagnostics sector, there are apprehensions regarding the company’s long-term valuation and growth trajectory.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.